Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is an immunology/inflammation drug developer. Its lead program, ATI-052, is in Phase 2 for atopic dermatitis and asthma (multiple indications planned). Its next catalyst on record is bosakitug (ATI-045): Top-line data from Phase 2 trial in atopic dermatitis (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: bosakitug (ATI-045) — Top-line data from Phase 2 trial in atopic dermatitis (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATI-052 | atopic dermatitis, asthma, eosinophilic esophagitis | antibody | Phase 2 |
| bosakitug (ATI-045) | atopic dermatitis | antibody | Phase 2 |
| modzatinib (ATI-2138) | lichen planus (oral erosive, cutaneous, lichen planopilaris) | small molecule | Phase 2 |
| lepzacitinib (ATI-1777) | atopic dermatitis | small molecule | Phase 1 |
| ATI-9494 | not specified | small molecule | Pre-clinical |
Recent results and decisions
- Oct 27, 2026positive ATI-052 achieved 45% placebo-adjusted mean improvement in EASI score at day 57 in Phase 1b atopic dermatitis trial.
Patients treated with ATI-052 experienced a 45% placebo-adjusted mean improvement in EASI score from baseline at day 57, reflecting a 58% mean improvement in the ATI-052 arm compared with a 13% mean improvement in the placebo arm.
Filing - Oct 27, 2026positive ATI-052 achieved 45% placebo-adjusted EASI improvement and 43% placebo-adjusted PP-NRS improvement at day 57 in Phase 1b POC trial in severe atopic dermatitis.
Patients treated with ATI-052 experienced a 45% placebo-adjusted mean improvement in EASI score from baseline at day 57, reflecting a 58% mean improvement in the ATI-052 arm compared with a 13% mean improvement in the placebo arm.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.